Efficacy, safety and survival with ruxolitinib in patients with myelofibrosis: results of a median 2-year follow-up of COMFORT-I

MLA

Srdan Verstovsek, et al. “Efficacy, Safety and Survival with Ruxolitinib in Patients with Myelofibrosis: Results of a Median 2-Year Follow-up of COMFORT-I.” Haematologica, vol. 98, no. 12, Dec. 2013. EBSCOhost, https://doi.org/10.3324/haematol.2013.092155.

APA

Srdan Verstovsek, Ruben A. Mesa, Jason Gotlib, Richard S. Levy, Vikas Gupta, John F. DiPersio, John V. Catalano, Michael W.N. Deininger, Carole B. Miller, Richard T. Silver, Moshe Talpaz, Elliott F. Winton, Jimmie H. Harvey, Murat O. Arcasoy, Elizabeth O. Hexner, Roger M. Lyons, Ronald Paquette, Azra Raza, Kris Vaddi, … Hagop M. Kantarjian. (2013). Efficacy, safety and survival with ruxolitinib in patients with myelofibrosis: results of a median 2-year follow-up of COMFORT-I. Haematologica, 98(12). https://doi.org/10.3324/haematol.2013.092155

Chicago

Srdan Verstovsek, Ruben A. Mesa, Jason Gotlib, Richard S. Levy, Vikas Gupta, John F. DiPersio, John V. Catalano, et al. 2013. “Efficacy, Safety and Survival with Ruxolitinib in Patients with Myelofibrosis: Results of a Median 2-Year Follow-up of COMFORT-I.” Haematologica 98 (12). doi:10.3324/haematol.2013.092155.